ReviewCytokine & growth factor reviews2020
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Bakiye Goker Bagca et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
71 papers cite itlatest 60 shown
this paperpooled ittrialcites it